OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press17710.17650/1818-8346-2016-11-1-14-23HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯGenetic heterogeneity of infant acute leukemiasГенетическая гетерогенность острых лейкозов у детей первого года жизниTsaurG. A.ЦаурГ. А.
Russian Federation
tsaur@mail.ruFleischmanE. W.ФлейшманЕ. В.
Russian Federation
PopovA. M.ПоповА. М.
Russian Federation
FechinaL. G.ФечинаЛ. Г.
Russian Federation
RumyantsevS. A.РумянцевС. А.
Russian Federation
Regional Children Clinical Hospital No 1ГБУЗ СО «Областная детская клиническая больница № 1»32 S. Deryabinoy St., Ekaterinburg, 620149, Russia Institute of Medical Cell TechnologiesРоссия, 620149, Екатеринбург, ул. С. Дерябиной, 32 ГАУЗ СО «Институт медицинских клеточных технологий»22a Karla Marksa St., Ekaterinburg, 620026, Russia Ural Federal University named after the first President of Russia B. N. Yel’tsinРоссия, 620026, Екатеринбург, ул. Карла Маркса, 22а ФГАОУ ВПО «Уральский федеральный университет им. первого Президента России Б. Н. Ельцина»19 Mira St., Ekaterinburg, 620002, RussiaРоссия, 620002, Екатеринбург, ул. Мира, 19N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» Минздрава России23 Kashirskoe Shosse, Moscow, 115478, RussiaРоссия, 115478, Москва, Каширское шоссе, 23Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» Минздрава России1 Samory Mashela St., Moscow, 117998, RussiaРоссия, 117998, Москва, ул. Саморы Машела, 132 S. Deryabinoy St., Ekaterinburg, 620149, RussiaРоссия, 620149, Екатеринбург, ул. С. Дерябиной, 321 Samory Mashela St., Moscow, 117998, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaРоссия, 117998, Москва, ул. Саморы Машела, 1 ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России1 Ostrovityanova St., Moscow, 117997, RussiaРоссия, 117997, Москва, ул. Островитянова, 13103201611114233103201631032016https://oncohematology.abvpress.ru/ongm/article/view/177

In this review we present current state of cytogenetic and molecular genetic diagnostics of various aberrations in infant acute leukemias together with our own experience in this field. A complex characteristic of acute leukemias was performed for both MLL-positive and MLL-negative patients. Genetic heterogeneity was shown. Common and rare cytogenetic and molecular genetic aberrations were presented.

В работе представлены литературные данные и собственные наблюдения за пациентами первого года жизни с острыми лейкозами. Комплексная характеристика острых лейкозов в этой возрастной группе с использованием данных цитогенетики, флуоресцентной гибридизации in situ, различных вариантов полимеразной цепной реакции как при наличии перестроек 11q23/MLL, так и при их отсутствии встречается крайне редко. Проанализированы как частые, так и редкие цитогенетические и молекулярно-генетические характеристики пациентов с острыми лимфобластными и острыми миелоидными лейкозами в данной возрастной группе.

infant acute leukemiacytogeneticsmolecular geneticsострые лейкозыдети первого года жизницитогенетикамолекулярная генетика1. Borkhardt A., Wuchter C., Viehmann S. et al. Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002;16(9):1685–90.Borkhardt A., Wuchter C., Viehmann S. et al. Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002;16(9):1685–90.2. Emerenciano M., Agudelo Arias D., Coser V. et al. Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia. Pediatr Blood Cancer 2006;47(5):549–54.Emerenciano M., Agudelo Arias D., Coser V. et al. Molecular cytogenetic findings of acute leukemia included in the Brazilian Collaborative Study Group of Infant acute leukemia. Pediatr Blood Cancer 2006;47(5):549–54.3. Chessells J., Harrison C., Kempski H. et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002;16(5):776–84.Chessells J., Harrison C., Kempski H. et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002;16(5):776–84.4. Reaman G., Zeltzer P., Bleyer W. et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children’s Cancer Study Group. J Clin Oncol 1985;3(11):1513–21.Reaman G., Zeltzer P., Bleyer W. et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children’s Cancer Study Group. J Clin Oncol 1985;3(11):1513–21.5. Greaves M. Infant leukemia biology, aetiology and treatment. Leukemia 1996;10(2):372–7.Greaves M. Infant leukemia biology, aetiology and treatment. Leukemia 1996;10(2):372–7.6. Dördelmann M., Reiter A., Borkhardt A. et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94(4):1209–17.Dördelmann M., Reiter A., Borkhardt A. et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94(4):1209–17.7. Pui C. H., Kane J., Crist W. Biology and treatment of infant leukemia. Leukemia 1995;9(5):762–9.Pui C. H., Kane J., Crist W. Biology and treatment of infant leukemia. Leukemia 1995;9(5):762–9.8. Biondi A., Cimino G., Pieters R. et al. Biological and therapeutic aspects of infant leukemia. Blood 2000;96(1):24–33.Biondi A., Cimino G., Pieters R. et al. Biological and therapeutic aspects of infant leukemia. Blood 2000;96(1):24–33.9. Crist W., Pullen J., Boyett J. et al. Clinical and biologic features predict a poor prognosis in cute lymphoid leukemias in infants: a Pediatric Oncology Group Study. Blood 1986;67(1):135–40.Crist W., Pullen J., Boyett J. et al. Clinical and biologic features predict a poor prognosis in cute lymphoid leukemias in infants: a Pediatric Oncology Group Study. Blood 1986;67(1):135–40.10. Möricke A., Zimmermann M., Reiter A. et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005;217(6):310–20.Möricke A., Zimmermann M., Reiter A. et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005;217(6):310–20.11. Pieters R., Schrappe M., De Lorenzo P. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370(9583):240–50.Pieters R., Schrappe M., De Lorenzo P. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370(9583):240–50.12. Tomizawa D., Koh K., Sato T. et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007;22(11):2258–63.Tomizawa D., Koh K., Sato T. et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007;22(11):2258–63.13. Цаур Г. А., Флейшман Е. В., Попов А. М. и др. Цитогенетическая и молекулярно-генетическая характеристика острых лейкозов у детей первого года жизни. Клиническая онкогематология 2011;4(2):134–41. [Tsaur G. A., Fleyshman E. V., Popov A. M. et al. Cytogenetics and molecular genetics of infant acute leukemias. Klinicheskaya onkogematologiya = Clinical Oncohematology 2011;4(2):134–41. (In Russ.)].Цаур Г. А., Флейшман Е. В., Попов А. М. и др. Цитогенетическая и молекулярно-генетическая характеристика острых лейкозов у детей первого года жизни. Клиническая онкогематология 2011;4(2):134–41. [Tsaur G. A., Fleyshman E. V., Popov A. M. et al. Cytogenetics and molecular genetics of infant acute leukemias. Klinicheskaya onkogematologiya = Clinical Oncohematology 2011;4(2):134–41. (In Russ.)].14. Цаур Г. А., Попов А. М., Алейникова О. В. и др. Характеристика перестроек 11q23(MLL) у детей первого года жизни с острым лимфобластным лейкозом. Онкогематология 2011;(3):57–64. [Tsaur G. A., Popov A. M., Aleynikova O. V. et al. Detection of 11q23(MLL) rearrangements in infant acute lymphoblastic leukemia. Onkogematologya = Oncohematology 2011;(3):57–64. (In Russ.)].Цаур Г. А., Попов А. М., Алейникова О. В. и др. Характеристика перестроек 11q23(MLL) у детей первого года жизни с острым лимфобластным лейкозом. Онкогематология 2011;(3):57–64. [Tsaur G. A., Popov A. M., Aleynikova O. V. et al. Detection of 11q23(MLL) rearrangements in infant acute lymphoblastic leukemia. Onkogematologya = Oncohematology 2011;(3):57–64. (In Russ.)].15. Цаур Г. А., Плеханова О. М., Гиндина Т. Л. и др. Применение метода флуоресцентной гибридизации in situ для выявления перестроек гена MLL при острых лейкозах у детей первого года жизни. Медицинская генетика 2012;(7):35–45. [Tsaur G. A., Plekhanova O. M., Gindina T. L. et al. Detection of MLL gene rearrangements in infants under 12 month of age with acute leukemias by fluorescence in situ hybridization. Meditsinskaya genetika = Medical Genetics 2012;(7):35–45. (In Russ.)].Цаур Г. А., Плеханова О. М., Гиндина Т. Л. и др. Применение метода флуоресцентной гибридизации in situ для выявления перестроек гена MLL при острых лейкозах у детей первого года жизни. Медицинская генетика 2012;(7):35–45. [Tsaur G. A., Plekhanova O. M., Gindina T. L. et al. Detection of MLL gene rearrangements in infants under 12 month of age with acute leukemias by fluorescence in situ hybridization. Meditsinskaya genetika = Medical Genetics 2012;(7):35–45. (In Russ.)].16. Aricò M., Valsecchi M. G., Camitta B. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998–1006.Aricò M., Valsecchi M. G., Camitta B. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998–1006.17. Nagayama J., Tomizawa D., Koh K. et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006;107(12):4663–5.Nagayama J., Tomizawa D., Koh K. et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006;107(12):4663–5.18. Felice M., Gallego M., Alonso C. et al. Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin–Frankfurt– Münster-based protocols. Leuk Lymphoma 2011;52(7):1215–21.Felice M., Gallego M., Alonso C. et al. Prognostic impact of t(1;19)/TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin–Frankfurt– Münster-based protocols. Leuk Lymphoma 2011;52(7):1215–21.19. Kager L., Lion T., Attarbaschi A. et al. Incidence and outcome of TCF3-PBX1- positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007;92(11):1561–4.Kager L., Lion T., Attarbaschi A. et al. Incidence and outcome of TCF3-PBX1- positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007;92(11):1561–4.20. Bhojwani D., Pei D., Sandlund J. et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012;26(2):265–70.Bhojwani D., Pei D., Sandlund J. et al. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012;26(2):265–70.21. Borkhardt A., Cazzaniga G., Viehmann S. et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Münster Study Group. Blood 1997;90(2):571–7.Borkhardt A., Cazzaniga G., Viehmann S. et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin–Frankfurt–Münster Study Group. Blood 1997;90(2):571–7.22. Pui C. H., Carroll W., Meshinchi S. et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551–65.Pui C. H., Carroll W., Meshinchi S. et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551–65.23. Moghrabi A., Levy D. E., Asselin B. et al. Results of the Dana-Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109(3):896–904.Moghrabi A., Levy D. E., Asselin B. et al. Results of the Dana-Farber cancer institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109(3):896–904.24. Moorman A., Ensor H., Richards S. et al.Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010;11(5):429–38.Moorman A., Ensor H., Richards S. et al.Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010;11(5):429–38.25. Nachman J., Heerema N., Sather H. et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007;110(4):1112–5.Nachman J., Heerema N., Sather H. et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007;110(4):1112–5.26. Den Boer M., van Slegtenhorst M., De Menezes R. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10(2):125–34.Den Boer M., van Slegtenhorst M., De Menezes R. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10(2):125–34.27. Dörge P., Meissner B., Zimmermann M. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013;98(3):428–32.Dörge P., Meissner B., Zimmermann M. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013;98(3):428–32.28. Chen I., Harvey R., Mullighan C. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2012;119(15):3512–22.Chen I., Harvey R., Mullighan C. et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2012;119(15):3512–22.29. Moorman A., Richards S., Robinson H. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007;109(6):2327–30.Moorman A., Richards S., Robinson H. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007;109(6):2327–30.30. Moorman A., Enshaei A., Schwab C. et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014;124(9):1434–44.Moorman A., Enshaei A., Schwab C. et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014;124(9):1434–44.31. Pui C. H., Kalwinsky D., Schell M. et al. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol 1988;6(6):1008–13.Pui C. H., Kalwinsky D., Schell M. et al. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol 1988;6(6):1008–13.32. Creutzig U., Zimmermann M., Bourquin J. P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26(4): 654–61.Creutzig U., Zimmermann M., Bourquin J. P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26(4): 654–61.33. Stevens R., Hann I., Wheatley K. et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998;101(1):130–40.Stevens R., Hann I., Wheatley K. et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998;101(1):130–40.34. Webb D., Harrison G., Stevens R. et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98(6):1714–20.Webb D., Harrison G., Stevens R. et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98(6):1714–20.35. Perel Y., Auvrignon A., Leblanc T. et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 2005;19(12):2082–9.Perel Y., Auvrignon A., Leblanc T. et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 2005;19(12):2082–9.36. Ishii E., Okamura J., Tsuchida M. et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 1991;19(1):28–32.Ishii E., Okamura J., Tsuchida M. et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. Med Pediatr Oncol 1991;19(1):28–32.37. Zweidler-McKay P., Hilden J. The ABCs of infant leukemia. Curr Probl Pediatr Adolesc Health Care 2008;38(3):78–94.Zweidler-McKay P., Hilden J. The ABCs of infant leukemia. Curr Probl Pediatr Adolesc Health Care 2008;38(3):78–94.38. Creutzig U., van den Heuvel-Eibrink M., Gibson B. et al Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120(16):3187–205.Creutzig U., van den Heuvel-Eibrink M., Gibson B. et al Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120(16):3187–205.39. Schoch C., Schnittger S., Klaus M. et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102(7):2395–402.Schoch C., Schnittger S., Klaus M. et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102(7):2395–402.40. Harrison C., Hills R., Moorman A. et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28(16):2674–81.Harrison C., Hills R., Moorman A. et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28(16):2674–81.41. von Neuhoff C., Reinhardt D., Sander A. et al. Prognostic impact of specific chromosomal aberrations in a large groupof pediatric patients with acute myeloid eukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010;28(16):2682–9.von Neuhoff C., Reinhardt D., Sander A. et al. Prognostic impact of specific chromosomal aberrations in a large groupof pediatric patients with acute myeloid eukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010;28(16):2682–9.42. Цаур Г. А., Флейшман Е. В., Гиндина Т. Л. и др. Характеристика перестроек 11q23/MLL при остром миелоидном лейкозе у детей первого года жизни. Клиническая онкогематология 2012;5(4):365–70. [Tsaur G. A., Fleyshman E. V., Gindina T. L. et al. Detection of 11q23/MLL rearrangements in infant acute myeloid leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(4):365–70. (In Russ.)].Цаур Г. А., Флейшман Е. В., Гиндина Т. Л. и др. Характеристика перестроек 11q23/MLL при остром миелоидном лейкозе у детей первого года жизни. Клиническая онкогематология 2012;5(4):365–70. [Tsaur G. A., Fleyshman E. V., Gindina T. L. et al. Detection of 11q23/MLL rearrangements in infant acute myeloid leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(4):365–70. (In Russ.)].43. Tosi S., Harbott J., Teigler-Schlegel A. et al. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2000;29(4):325–32.Tosi S., Harbott J., Teigler-Schlegel A. et al. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2000;29(4):325–32.44. Carroll A., Civin C., Schneider N. et al. The t(1;22)(p13;q13) is non-random and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 1991;78(3):748–52.Carroll A., Civin C., Schneider N. et al. The t(1;22)(p13;q13) is non-random and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood 1991;78(3):748–52.45. Manola K. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009;83(5):391–405.Manola K. Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 2009;83(5):391–405.46. Bernstein J., Dastugue N., Haas O. et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia 2000;14(14):216–8.Bernstein J., Dastugue N., Haas O. et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia 2000;14(14):216–8.47. Raimondi S., Chang M. N., Ravindranath Y. et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94(11):3707–16.Raimondi S., Chang M. N., Ravindranath Y. et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94(11):3707–16.48. Martinez-Climent J., Garcia-Conde J. Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J Pediatr Hematol Oncol 1999;21(2):91–102.Martinez-Climent J., Garcia-Conde J. Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J Pediatr Hematol Oncol 1999;21(2):91–102.49. Lion T., Haas O. Acute megakaryocytic leukemia with the t(1;22)(p13;q13). Leuk Lymphoma 1993;11(1–2):15–20.Lion T., Haas O. Acute megakaryocytic leukemia with the t(1;22)(p13;q13). Leuk Lymphoma 1993;11(1–2):15–20.50. Haas O., Kronberger M., Mayerhofer L. Cytogenetic abnormalities associated with childhood acute myeloblastic leukemia. Recent Results Cancer Res 1993;131:103–12.Haas O., Kronberger M., Mayerhofer L. Cytogenetic abnormalities associated with childhood acute myeloblastic leukemia. Recent Results Cancer Res 1993;131:103–12.51. Dastugue N., Lafage-Pochitaloff M., Pagès M. et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002;100(2):618–26.Dastugue N., Lafage-Pochitaloff M., Pagès M. et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 2002;100(2):618–26.52. Vormoor J., Boos J., Stahnke K. et al. Therapy of childhood acute myelogenous leukemias. Ann Hematol 1996;73(1):11–24.Vormoor J., Boos J., Stahnke K. et al. Therapy of childhood acute myelogenous leukemias. Ann Hematol 1996;73(1):11–24.53. Reinhardt D., Diekamp S., Langebrake C. et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down’s syndrome: improved outcome with intensified induction treatment. Leukemia 2005;19(8):1495–6.Reinhardt D., Diekamp S., Langebrake C. et al. Acute megakaryoblastic leukemia in children and adolescents, excluding Down’s syndrome: improved outcome with intensified induction treatment. Leukemia 2005;19(8):1495–6.54. Athale U., Razzouk B., Raimondi S. et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood 2001;97(12):3727–32.Athale U., Razzouk B., Raimondi S. et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood 2001;97(12):3727–32.55. Barnard D., Alonzo T., Gerbing R. et al. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group. Pediatr Blood Cancer 2007;49(1):17–22.Barnard D., Alonzo T., Gerbing R. et al. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group. Pediatr Blood Cancer 2007;49(1):17–22.56. Tsukimoto I., Tawa A., Horibe K. et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009;27(24):4007–13.Tsukimoto I., Tawa A., Horibe K. et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009;27(24):4007–13.57. Wlodarska I., La Starza R., Baens M. et al. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998;91(4):1399–406.Wlodarska I., La Starza R., Baens M. et al. Fluorescence in situ hybridization characterization of new translocations involving TEL (ETV6) in a wide spectrum of hematologic malignancies. Blood 1998;91(4):1399–406.58. Tosi S., Hughes J., Scherer S. et al. Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003;38(2):191–200.Tosi S., Hughes J., Scherer S. et al. Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003;38(2):191–200.59. von Bergh A., van Drunen E., van Wering E. et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 2006;45(8):731–9.von Bergh A., van Drunen E., van Wering E. et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer 2006;45(8):731–9.60. Slater R., von Drunen E., Kroes W. et al. t(7;12)(q36;p13) and t(7;12)(q32;p13) translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001;15(6):915–20.Slater R., von Drunen E., Kroes W. et al. t(7;12)(q36;p13) and t(7;12)(q32;p13) translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001;15(6):915–20.61. Simmons H., Oseth L., Nguyen P. et al. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 2002;16(12):2408–16.Simmons H., Oseth L., Nguyen P. et al. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 2002;16(12):2408–16.62. Breems D., van Putten W., de Greef G. et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26(29):4791–7.Breems D., van Putten W., de Greef G. et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26(29):4791–7.63. Raza S., TaherNazerHussain F., Patnaik M. et al. Autosomal monosomies among 24262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Am J Hematol 2011;86(4):353–6.Raza S., TaherNazerHussain F., Patnaik M. et al. Autosomal monosomies among 24262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Am J Hematol 2011;86(4):353–6.64. Haferlach C., Alpermann T., Schnittger S. et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012;119(9):2122–5.Haferlach C., Alpermann T., Schnittger S. et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2012;119(9):2122–5.65. Pession A., Masetti R., Rizzari C. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122(2):170–8.Pession A., Masetti R., Rizzari C. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122(2):170–8.66. Manola K., Panitsas F., Polychronopoulou S. et al. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet 2013;206(3):63–72.Manola K., Panitsas F., Polychronopoulou S. et al. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet 2013;206(3):63–72.67. Ford A., Ridge S., Cabrera M. et al. In utero rearrangements in the trithoraxrelated oncogene in infant leukaemias. Nature 1993;363(6427):358–60.Ford A., Ridge S., Cabrera M. et al. In utero rearrangements in the trithoraxrelated oncogene in infant leukaemias. Nature 1993;363(6427):358–60.68. Greaves M., Maia A., Wiemels J. et al. Leukemia in twins: lessons in natural history. Blood 2003;102(7):2321–33.Greaves M., Maia A., Wiemels J. et al. Leukemia in twins: lessons in natural history. Blood 2003;102(7):2321–33.69. Strong S., Corney G. The placenta in twin pregnancy. Oxford: Pergamon Press, 1967. 107 p.Strong S., Corney G. The placenta in twin pregnancy. Oxford: Pergamon Press, 1967. 107 p.70. Clarkson B., Boyse E. Possible explanation of the high concordance for acute leukaemia in monozygotic twins. Lancet 1971;1(7701):699–701.Clarkson B., Boyse E. Possible explanation of the high concordance for acute leukaemia in monozygotic twins. Lancet 1971;1(7701):699–701.71. Wolman I. Parallel responses to chemotherapy in identical twin infants with concordant leukemia. J Pediatr 1962;60:91–5.Wolman I. Parallel responses to chemotherapy in identical twin infants with concordant leukemia. J Pediatr 1962;60:91–5.72. Gill Super H., Rothberg P., Kobayashi H. et al. Clonal, nonconstitutional rearrangementsGill Super H., Rothberg P., Kobayashi H. et al. Clonal, nonconstitutional rearrangementsof the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. Blood 1994;83(3):641–4.73. Gale K., Ford A., Repp R. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94(25):13950–4.Gale K., Ford A., Repp R. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94(25):13950–4.74. Chuk M., McIntyre E., Small D. et al. Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood 2009;113(26):6691–4.Chuk M., McIntyre E., Small D. et al. Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood 2009;113(26):6691–4.75. Knudson A. Stem cell regulation, tissue ontogeny, and oncogenic events. Semin Cancer Biol 1992;3(3):99–106Knudson A. Stem cell regulation, tissue ontogeny, and oncogenic events. Semin Cancer Biol 1992;3(3):99–106